Physician profile
Mohammad Bitar
NPI 1487877973
$1,279.12
in general payments reported to CMS, 2019-2025
11 companies · $519 in 2025
The $519 reported for 2025 was more than what 93% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.40 · 2020: $59.56 · 2021: $90.88 · 2022: $137 · 2023: $106 · 2024: $304 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $354.52 | 2024-2025 | Qelbree |
| Cranial Technologies, INC | $242.23 | 2019-2025 | Doc Band |
| Pfizer INC. | $206.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $200.80 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbvie INC. | $73.44 | 2022 | |
| Sanofi Pasteur INC. | $63.64 | 2019-2023 | |
| Cipher Pharmaceuticals US LLC | $41.11 | 2025 | Spinosad, Natroba |
| Glaxosmithkline, LLC. | $30.65 | 2019-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $29.27 | 2019-2020 | |
| United Therapeutics Corporation | $20.99 | 2023 | Orenitram, Tyvaso |
| Phadia US INC. | $15.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.